JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online May 14, 2009, 10.2967/jnumed.108.058529
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.108.058529v1
50/6/878    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lowe, V. J.
Right arrow Articles by Petersen, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lowe, V. J.
Right arrow Articles by Petersen, R. C.
Journal of Nuclear Medicine Vol. 50 No. 6 878-886
© 2009 by Society of Nuclear Medicine
doi: 10.2967/jnumed.108.058529

Clinical Investigation

Comparison of 18F-FDG and PiB PET in Cognitive Impairment

Val J. Lowe1, Bradley J. Kemp1, Clifford R. Jack, Jr.1, Matthew Senjem2, Stephen Weigand3, Maria Shiung1, Glenn Smith4, David Knopman5, Bradley Boeve5, Brian Mullan1 and Ronald C. Petersen5

1 Department of Radiology, Mayo Clinic, Rochester, Minnesota; 2 Department of Information Technology, Mayo Clinic, Rochester, Minnesota; 3 Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota; 4 Department of Psychology, Mayo Clinic, Rochester, Minnesota; and 5 Department of Neurology, Mayo Clinic, Rochester, Minnesota

Correspondence: For correspondence or reprints contact: Val J. Lowe, Mayo Clinic, 200 First St. SW, Rochester, MN 55905. E-mail: vlowe{at}mayo.edu

The purpose of this study was to compare the diagnostic accuracy of glucose metabolism and amyloid deposition as demonstrated by 18F-FDG and Pittsburg Compound B (PiB) PET to evaluate subjects with cognitive impairment. Methods: Subjects were selected from existing participants in the Mayo Alzheimer's Disease Research Center or Alzheimer's Disease Patient Registry programs. A total of 20 healthy controls and 17 amnestic mild cognitive impairment (aMCI), 6 nonamnestic mild cognitive impairment (naMCI), and 13 Alzheimer disease (AD) subjects were imaged with both PiB and 18F-FDG PET between March 2006 and August 2007. Global measures for PiB and 18F-FDG PET uptake, normalized to cerebellum for PiB and pons for 18F-FDG, were compared. Partial-volume correction, standardized uptake value (SUV), and cortical ratio methods of image analysis were also evaluated in an attempt to optimize the analysis for each test. Results: Significant discrimination (P < 0.05) between controls and AD, naMCI and aMCI, naMCI and AD, and aMCI and AD by PiB PET measurements was observed. The paired groupwise comparisons of the global measures demonstrated that PiB PET versus 18F-FDG PET showed similar significant group separation, with only PiB showing significant separation of naMCI and aMCI subjects. Conclusion: PiB PET and 18F-FDG PET have similar diagnostic accuracy in early cognitive impairment. However, significantly better group discrimination in naMCI and aMCI subjects by PiB, compared with 18F-FDG, was seen and may suggest early amyloid deposition before cerebral metabolic disruption in this group.

Key Words: PET • dementia • 18F-FDG • PiB

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2009 by the Society of Nuclear Medicine.